|
Mar 17
|
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal
|
|
Mar 17
|
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
|
|
Mar 17
|
AstraZeneca to buy EsoBiotec for up to $1 billion
|
|
Mar 17
|
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
|
|
Mar 14
|
AstraZeneca Stock Scores RS Rating Upgrade
|
|
Mar 14
|
INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants
|
|
Mar 14
|
AstraZeneca director says AI must be a “thought partner” in drug discovery
|
|
Mar 14
|
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
|
|
Mar 13
|
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market
|
|
Mar 13
|
Why Is CRISPR Therapeutics (CRSP) Up 0.4% Since Last Earnings Report?
|
|
Mar 12
|
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
|
|
Mar 12
|
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
|
|
Mar 11
|
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
|
|
Mar 10
|
AstraZeneca and Ionis win EU approval for ATTR polyneuropathy
|
|
Mar 10
|
AstraZeneca reports positive outcomes from trial of Imfinzi
|
|
Feb 26
|
AstraZeneca PLC (AZN): One of the Best Vaccine Stocks to Buy According to Hedge Funds
|
|
Feb 26
|
AstraZeneca breast cancer drug shows positive results, shares up
|
|
Feb 26
|
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
|
|
Feb 24
|
AstraZeneca PLC (AZN): A High Growth Mega Cap Stock You Can Buy and Hold for the Next 5 Years
|
|
Feb 24
|
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
|